These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 9166535)

  • 1. P53 immunostaining predicts chemosensitivity in non-small cell lung cancer: A preliminary report.
    Kawasaki M; Nakanishi Y; Yatsunami J; Takayama K; Ochiai S; Xinhai P; Kuwano K; Hara N
    Cancer J Sci Am; 1996; 2(4):217-20. PubMed ID: 9166535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.
    Kawasaki M; Nakanishi Y; Kuwano K; Yatsunami J; Takayama K; Hara N
    Clin Cancer Res; 1997 Jul; 3(7):1195-200. PubMed ID: 9815799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of p53 gene in stage IIIA non-small cell lung cancer in patients after neoadjuvant chemotherapy with Vepesid and Cisplatin.
    Mańdziuk S; Dudzisz-Sledź M; Korszeń-Pilecka I; Milanowski J; Wojcierowski J; Korobowicz E
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):154-7. PubMed ID: 15314976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer.
    Rusch V; Klimstra D; Venkatraman E; Oliver J; Martini N; Gralla R; Kris M; Dmitrovsky E
    Cancer Res; 1995 Nov; 55(21):5038-42. PubMed ID: 7585548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
    Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
    Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis.
    Yüksel M; Cermik TF; Doğanay L; Karlikaya C; Cakir E; Salan A; Berkarda S
    Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):876-81. PubMed ID: 12111127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical study of p53 in non-small cell lung cancer before and after preoperative chemotherapy.
    Korobowicz E; Zdunek M
    Pol J Pathol; 2000; 51(2):71-6. PubMed ID: 10974929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer.
    Miyatake K; Gemba K; Ueoka H; Nishii K; Kiura K; Tabata M; Shibayama T; Takigawa N; Kawaraya M; Tanimoto M
    Anticancer Res; 2003; 23(3C):2829-36. PubMed ID: 12926120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical expression of glutathione S-transferase-Pi can predict chemotherapy response in patients with nonsmall cell lung carcinoma.
    Bai F; Nakanishi Y; Kawasaki M; Takayama K; Yatsunami J; Pei XH; Tsuruta N; Wakamatsu K; Hara N
    Cancer; 1996 Aug; 78(3):416-21. PubMed ID: 8697385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].
    Cheng C; Wu YL; Gu LJ; Chen G; Weng YM; Feng WN; Zhong WZ
    Ai Zheng; 2005 Jul; 24(7):846-9. PubMed ID: 16004813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
    Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
    Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [P53 protein expression and chemosensitivity to cisplatin in patients with non-small cell lung cancer: a meta-analysis].
    Wang JL; Jiao SC; Ye P; Li JY
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):770-3. PubMed ID: 18504201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
    Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M
    Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
    Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
    Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 Gene status in relation to ex vivo chemosensitivity of non-small cell lung cancer.
    Vogt U; Zaczek A; Klinke F; Granetzny A; Bielawski K; Falkiewicz B
    J Cancer Res Clin Oncol; 2002 Mar; 128(3):141-7. PubMed ID: 11935300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of p21 and bcl-2 proteins in paraffin-embedded preparations of non-small cell lung cancer in stage IIIA after Etoposide and Cisplatin induced chemotherapy.
    Mańdziuk S; Dudzisz-Sledź M; Korszeń-Pilecka I; Milanowski J; Wojcierowski J; Korobowicz E
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):149-53. PubMed ID: 15314975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined chemotherapy and differentiation therapy in the treatment of advanced non-small-cell lung cancer.
    Recchia F; Sica G; De Filippis S; Rea S; Frati L
    Anticancer Res; 1997; 17(5B):3761-5. PubMed ID: 9427776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcl-2 expression as a predictor of chemosensitivities and survival in small cell lung cancer.
    Takayama K; Ogata K; Nakanishi Y; Yatsunami J; Kawasaki M; Hara N
    Cancer J Sci Am; 1996; 2(4):212-6. PubMed ID: 9166534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.